Through Bcl‐2 inhibition, venetoclax alleviated the resistance of AML cells to granzyme B/perforin‐mediated killing, amplifying the anti‐leukaemic effects of ICT01‐activated γ9δ2 T cells, NK cells, and CD8+ T cells. This evidence concerns the gene CD8A and acute myeloid leukemia.